Metabolic Conferences
Round Up
ADA and EASL 2023
Watch out, Novo Nordisk. Lilly’s retatrutide, a so-called triple G, has bettered not only Novo’s Wegovy but Lilly’s own Mounjaro when data from three...
ADA
Lilly unveils its triple threat
Biomea claims disease modification in diabetes
Vertex raises hopes of type 1 diabetes cure
Toxicity undermines Boehringer and Zealand’s incretin
ADA 2023 preview – Lilly’s oral obesity data leave room for Pfizer
EASL
Biomarkers back a new Nash player
GLP-1 combos take on a milder form of Nash
Madrigal denies pivotal endpoint change